Vimian Group AB (publ)

OM:VIMIAN Stock Report

Market Cap: SEK 22.0b

Vimian Group Valuation

Is VIMIAN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VIMIAN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
SEK 39.57
Fair Value
5.6% overvalued intrinsic discount
5
Number of Analysts

Below Fair Value: VIMIAN (SEK41.8) is trading above our estimate of fair value (SEK39.57)

Significantly Below Fair Value: VIMIAN is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VIMIAN?

Key metric: As VIMIAN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for VIMIAN. This is calculated by dividing VIMIAN's market cap by their current earnings.
What is VIMIAN's PE Ratio?
PE Ratio101.3x
Earnings€19.30m
Market Cap€1.95b

Price to Earnings Ratio vs Peers

How does VIMIAN's PE Ratio compare to its peers?

The above table shows the PE ratio for VIMIAN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average71.5x
ASKER Asker Healthcare Group
104.3x24.42%SEK 39.8b
XVIVO Xvivo Perfusion
67.2x45.49%SEK 9.2b
EKTA B Elekta
79x27.47%SEK 18.7b
GETI B Getinge
35.5x25.00%SEK 52.5b
VIMIAN Vimian Group
101.3x44.22%SEK 22.0b

Price-To-Earnings vs Peers: VIMIAN is expensive based on its Price-To-Earnings Ratio (101.3x) compared to the peer average (67.8x).

Price to Earnings Ratio vs Industry

How does VIMIAN's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
VIMIAN 101.3xIndustry Avg. 32.5xNo. of Companies10PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: VIMIAN is expensive based on its Price-To-Earnings Ratio (101.3x) compared to the European Medical Equipment industry average (32.5x).

Price to Earnings Ratio vs Fair Ratio

What is VIMIAN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VIMIAN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio101.3x
Fair PE Ratio68.5x

Price-To-Earnings vs Fair Ratio: VIMIAN is expensive based on its Price-To-Earnings Ratio (101.3x) compared to the estimated Fair Price-To-Earnings Ratio (68.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VIMIAN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 41.80
SEK 45.35
+8.50%
12.03%SEK 51.65SEK 37.35n/a5
Jun ’26SEK 46.00
SEK 46.28
+0.60%
13.56%SEK 54.63SEK 36.75n/a6
May ’26SEK 38.96
SEK 46.41
+19.13%
13.42%SEK 55.04SEK 37.03n/a6
Apr ’26SEK 44.50
SEK 48.17
+8.25%
14.16%SEK 55.12SEK 38.31n/a6
Mar ’26SEK 40.35
SEK 46.69
+15.72%
15.23%SEK 54.67SEK 34.82n/a6
Feb ’26SEK 40.65
SEK 47.58
+17.04%
15.40%SEK 54.94SEK 35.77n/a6
Jan ’26SEK 39.80
SEK 47.92
+20.40%
15.57%SEK 55.21SEK 35.88n/a6
Dec ’25SEK 44.85
SEK 47.92
+6.84%
15.57%SEK 55.21SEK 35.88n/a6
Nov ’25SEK 43.95
SEK 46.06
+4.80%
22.42%SEK 55.08SEK 28.20n/a6
Oct ’25SEK 45.95
SEK 43.98
-4.29%
22.90%SEK 55.01SEK 27.76n/a7
Sep ’25SEK 42.85
SEK 41.06
-4.17%
19.96%SEK 51.02SEK 27.53n/a7
Aug ’25SEK 33.70
SEK 40.52
+20.23%
17.34%SEK 50.50SEK 28.47n/a7
Jul ’25SEK 33.80
SEK 38.03
+12.50%
17.60%SEK 47.96SEK 27.30SEK 39.887
Jun ’25SEK 34.95
SEK 39.12
+11.94%
18.83%SEK 50.47SEK 27.92SEK 46.007
May ’25SEK 30.30
SEK 39.36
+29.91%
22.51%SEK 51.52SEK 27.13SEK 38.966
Apr ’25SEK 32.50
SEK 38.69
+19.03%
22.51%SEK 50.36SEK 27.01SEK 44.506
Mar ’25SEK 30.24
SEK 39.01
+28.99%
20.80%SEK 49.97SEK 27.84SEK 40.357
Feb ’25SEK 28.68
SEK 37.55
+30.94%
18.77%SEK 48.91SEK 28.20SEK 40.657
Jan ’25SEK 29.60
SEK 37.01
+25.03%
18.78%SEK 47.99SEK 27.67SEK 39.807
Dec ’24SEK 26.28
SEK 38.05
+44.77%
20.27%SEK 48.86SEK 27.33SEK 44.856
Nov ’24SEK 26.02
SEK 42.67
+63.99%
16.82%SEK 49.92SEK 28.43SEK 43.956
Oct ’24SEK 23.84
SEK 44.34
+85.97%
9.86%SEK 49.95SEK 36.97SEK 45.956
Sep ’24SEK 33.08
SEK 44.20
+33.61%
9.86%SEK 49.78SEK 36.84SEK 42.856
Aug ’24SEK 27.26
SEK 43.78
+60.59%
9.06%SEK 50.99SEK 38.12SEK 33.706
Jul ’24SEK 25.60
SEK 44.76
+74.83%
9.00%SEK 51.82SEK 38.74SEK 33.806
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
SEK 45.35
Fair Value
7.8% undervalued intrinsic discount
5
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/06 00:47
End of Day Share Price 2025/07/04 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vimian Group AB (publ) is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Hassan Al-WakeelBarclays
Blanka PorkolabBarclays